Sahajanand Medical IPO Day 4: GMP ₹15 (₹-20)
Welcome back, investors! It’s Day 4 of the Sahajanand Medical IPO subscription period, and we’re here to break down the latest numbers. The IPO, which opened on October 15th and is set to close on October 19th, is offering shares at an issue price of ₹344. Today marks a crucial point as we approach the final days of the offering. Let’s dive into the subscription status and the ever-important Grey Market Premium (GMP) to see how things are shaping up.
| Date | GMP | Est. Listing |
|---|---|---|
| 22 Oct | +₹18 | ₹362 |
| 21 Oct | +₹22 | ₹366 |
| 20 Oct | +₹25 | ₹369 |
| 19 Oct | +₹23 | ₹367 |
| 18 Oct | +₹28 | ₹372 |
Subscription Status
As of the end of Day 4, the subscription numbers for Sahajanand Medical IPO are showing zero across all categories: Retail, Non-Institutional Investors (NII), and Qualified Institutional Buyers (QIB). This is quite unusual and frankly, a little concerning for a mainboard IPO nearing its closing date. Typically, by Day 4, we’d expect to see at least some traction, especially in the retail segment. The absence of any subscriptions from QIBs and NIIs, who are often the early birds and significant contributors to IPO success, is particularly noteworthy. This could indicate a wait-and-watch approach from these institutional players, or perhaps a lack of immediate conviction. However, with two more days left, there’s still time for a last-minute surge. The bottom line is, as of now, the IPO hasn’t seen any demand materialize.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 3.04x | |
| NII / HNI | 14.64x | |
| QIB | 34.70x | |
| Total | 34.70x |
GMP Update
Now, let’s talk about the Grey Market Premium (GMP). Yesterday, Sahajanand Medical IPO was trading at a GMP of ₹35. Today, the GMP has seen a significant drop to ₹15. This represents a decrease of ₹20 from the previous day. A declining GMP is never ideal, and a drop of this magnitude, especially when subscription numbers are also stagnant, can be a red flag for potential investors. The expected listing price, which was around ₹359 based on yesterday’s GMP (₹344 issue price + ₹15 profit), now looks less certain. While a positive GMP still suggests a potential listing gain, the sharp decline warrants caution. It suggests that the market sentiment might be cooling off, or perhaps the lack of subscription is weighing on the grey market sentiment.
Should You Apply?
This is the million-dollar question, and it’s a tough one given the current data. On one hand, Sahajanand Medical is a mainboard IPO, and a listing gain is always attractive. The lot size is 43 shares, meaning an investment of ₹14,792 at the issue price (43 shares * ₹344). However, the complete lack of subscription numbers on Day 4 is a major concern. It’s highly unusual and suggests that investors, particularly the institutional ones, aren’t rushing in. Coupled with the sharp decline in GMP, it paints a picture of uncertainty.
SEBI registered investment advisors often emphasize the importance of looking at both subscription levels and market sentiment (reflected in GMP). In this scenario, both indicators are currently pointing towards a cautious approach. While there’s still time for things to change, the current trend isn’t exactly confidence-inspiring. You’ll want to monitor the subscription numbers closely on Day 5 and Day 6, and keep an eye on the GMP. If subscriptions remain flat and GMP continues to slide, it might be prudent to wait and watch the listing. Conversely, a sudden surge in subscriptions and a stabilizing GMP could change the narrative. Remember, it’s always wise to do your own research and consult with a financial advisor before making any investment decisions.